Smoking and therapeutic response to clozapine in patients with schizophrenia
- Joseph P. McEvoy(corresponding author),
- Oliver Freudenreich,
- William H. Wilson
- Duke University,
- Robert Wood Johnson University Hospital
Abstract
Background: Of patients with schizophrenia, 70 to 80% smoke. Nicotine corrects certain information processing and cognitive psychomotor deficits seen in many patients with schizophrenia. Clozapine, but not conventional antipsychotics, has been shown to correct some of these deficits. Methods: We assessed psychopathology and smoking in 70 patients with treatment refractory schizophrenia (55 smokers and 15 nonsmokers) at baseline when they were receiving conventional antipsychotics and again after they were switched to clozapine. Results: Smokers showed significantly greater therapeutic response to clozapine than nonsmokers. Smokers smoked less when treated with clozapine than when treated with conventional antipsychotics. Conclusions: Certain patients with schizophrenia have contributing pathophysiologic mechanisms that respond favorably to either nicotine or clozapine. Copyright (C) 1999 Society of Biological Psychiatry.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 125-129 (5 pages)Journal (Volume, Issue Number)
Biological Psychiatry (Volume 46, Issue 1)Publication milestones
- Published - 07/1999
Publication status
ISSN
0006-3223Publication IDs
- Scopus: 0033027553
- PubMed: 10394482
